The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402).
 
Yuji Miyamoto
No Relationships to Disclose
 
Satoshi Yuki
No Relationships to Disclose
 
Mototsugu Shimokawa
No Relationships to Disclose
 
Hiroaki Tanioka
No Relationships to Disclose
 
Akihito Tsuji
Honoraria - Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical
 
Masako Asayama
No Relationships to Disclose
 
Takeshi Shiraishi
No Relationships to Disclose
 
Masahito Kotaka
No Relationships to Disclose
 
Akitaka Makiyama
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Lilly Japan; MSD; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Satohiro Masuda
No Relationships to Disclose
 
Takuhiro Yamaguchi
No Relationships to Disclose
 
Hiroshi Saeki
No Relationships to Disclose
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yasunori Emi
No Relationships to Disclose
 
Hideo Baba
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Bayer Yakuhin (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Yoshihiko Maehara
Speakers' Bureau - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Lilly Japan (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)